[pending] BENLYSTA (BELIMUMAB)
Pending LLM rewrite. Source: FDA_DRUG D-0540-2025.
- Product
- BENLYSTA — BENLYSTA (BELIMUMAB)
- Category
- Drug
- Distribution
- 3 states
Category
FDA recalls of prescription and over-the-counter drugs.
FDA drug recalls cover prescription medicines, over-the-counter products, biologic and gene therapies, and active pharmaceutical ingredients (the raw drug substances that manufacturers compound into finished products). Recall classifications follow the same Class I / II / III system as food, and most published recalls are Class II — the product is unlikely to cause permanent harm but doesn't meet specification.
The most common reasons for a drug recall are out-of-specification potency or dissolution (the active ingredient is present in too high or too low a dose), microbial contamination, particulate matter in injectables, mix-ups during packaging where bottles end up with the wrong tablets, and nitrosamine impurities in certain drug classes. Many drug recalls are at the lot level — the manufacturer's whole product line is still safe to use, but specific production lots are pulled.
If a recall affects your medication: don't stop taking it on your own. Call your prescriber or pharmacist before doing anything. Stopping a prescribed drug abruptly can be more dangerous than the issue prompting the recall. Most drug-recall remedies route through the dispensing pharmacy, who'll either swap your supply for an unaffected lot or coordinate a refund with the manufacturer.
Pending LLM rewrite. Source: FDA_DRUG D-0540-2025.
Pending LLM rewrite. Source: FDA_DRUG D-0535-2025.
Pending LLM rewrite. Source: FDA_DRUG D-0539-2025.
Pending LLM rewrite. Source: FDA_DRUG D-0536-2025.
Pending LLM rewrite. Source: FDA_DRUG D-0533-2025.
Pending LLM rewrite. Source: FDA_DRUG D-0516-2025.
Pending LLM rewrite. Source: FDA_DRUG D-0532-2025.
Pending LLM rewrite. Source: FDA_DRUG D-0519-2025.
Pending LLM rewrite. Source: FDA_DRUG D-0530-2025.
Pending LLM rewrite. Source: FDA_DRUG D-0520-2025.
Pending LLM rewrite. Source: FDA_DRUG D-0550-2025.
Pending LLM rewrite. Source: FDA_DRUG D-0525-2025.
Pending LLM rewrite. Source: FDA_DRUG D-0522-2025.
Pending LLM rewrite. Source: FDA_DRUG D-0518-2025.
Pending LLM rewrite. Source: FDA_DRUG D-0521-2025.
Pending LLM rewrite. Source: FDA_DRUG D-0548-2025.
Pending LLM rewrite. Source: FDA_DRUG D-0523-2025.
Pending LLM rewrite. Source: FDA_DRUG D-0549-2025.
Pending LLM rewrite. Source: FDA_DRUG D-0524-2025.
Pending LLM rewrite. Source: FDA_DRUG D-0534-2025.
Pending LLM rewrite. Source: FDA_DRUG D-0517-2025.
Pending LLM rewrite. Source: FDA_DRUG D-0514-2025.
Pending LLM rewrite. Source: FDA_DRUG D-0512-2025.
Pending LLM rewrite. Source: FDA_DRUG D-0509-2025.
Pending LLM rewrite. Source: FDA_DRUG D-0511-2025.
Looking for a different category? Browse all recalls.